SI2068880T1 - Postopek za zdravljenje raka, ki vsebuje mutacije EGFR - Google Patents
Postopek za zdravljenje raka, ki vsebuje mutacije EGFRInfo
- Publication number
- SI2068880T1 SI2068880T1 SI200730957T SI200730957T SI2068880T1 SI 2068880 T1 SI2068880 T1 SI 2068880T1 SI 200730957 T SI200730957 T SI 200730957T SI 200730957 T SI200730957 T SI 200730957T SI 2068880 T1 SI2068880 T1 SI 2068880T1
- Authority
- SI
- Slovenia
- Prior art keywords
- egfr
- treatment
- tumor
- hki
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 230000035772 mutation Effects 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108060006698 EGF receptor Proteins 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 4
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 abstract 3
- 229940121647 egfr inhibitor Drugs 0.000 abstract 2
- 230000002427 irreversible effect Effects 0.000 abstract 2
- NERXPXBELDBEPZ-RMKNXTFCSA-N (e)-n-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 NERXPXBELDBEPZ-RMKNXTFCSA-N 0.000 abstract 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 abstract 1
- ULXXDDBFHOBEHA-INIZCTEOSA-N N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)C=CCN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-INIZCTEOSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 229960001686 afatinib Drugs 0.000 abstract 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229950008835 neratinib Drugs 0.000 abstract 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 abstract 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011363 radioimmunotherapy Methods 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000002271 resection Methods 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06120856 | 2006-09-18 | ||
| EP07101505 | 2007-01-31 | ||
| EP07820235A EP2068880B1 (en) | 2006-09-18 | 2007-09-14 | Method for treating cancer harboring egfr mutations |
| PCT/EP2007/059735 WO2008034776A1 (en) | 2006-09-18 | 2007-09-14 | Method for treating cancer harboring egfr mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2068880T1 true SI2068880T1 (sl) | 2012-08-31 |
Family
ID=38698376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200730957T SI2068880T1 (sl) | 2006-09-18 | 2007-09-14 | Postopek za zdravljenje raka, ki vsebuje mutacije EGFR |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8877764B2 (https=) |
| EP (1) | EP2068880B1 (https=) |
| JP (1) | JP2010503717A (https=) |
| KR (1) | KR20090074202A (https=) |
| AT (1) | ATE552835T1 (https=) |
| AU (1) | AU2007299080B2 (https=) |
| BR (1) | BRPI0717586A2 (https=) |
| CA (1) | CA2663599A1 (https=) |
| CY (1) | CY1112896T1 (https=) |
| DK (1) | DK2068880T3 (https=) |
| ES (1) | ES2385613T3 (https=) |
| IL (1) | IL197605A0 (https=) |
| MX (1) | MX2009002710A (https=) |
| NZ (1) | NZ576065A (https=) |
| PL (1) | PL2068880T3 (https=) |
| PT (1) | PT2068880E (https=) |
| RU (1) | RU2492864C2 (https=) |
| SI (1) | SI2068880T1 (https=) |
| WO (1) | WO2008034776A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE04748B1 (et) * | 1999-06-21 | 2006-12-15 | Boehringer Ingelheim Pharma Kg | Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks |
| US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| DE10349113A1 (de) * | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| ES2364495T3 (es) | 2005-02-03 | 2011-09-05 | The General Hospital Corporation | Método para tratar cáncer resistente a gefitinib. |
| JP2009514870A (ja) | 2005-11-04 | 2009-04-09 | ワイス | ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ |
| PL1948180T3 (pl) * | 2005-11-11 | 2013-09-30 | Boehringer Ingelheim Int | Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2 |
| CA2833706C (en) * | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| JP5241513B2 (ja) | 2006-01-26 | 2013-07-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミノクロトニルアミノ置換キナゾリン誘導体の合成方法 |
| AU2007299080B2 (en) | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| PE20100252A1 (es) * | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| ES2692769T3 (es) | 2008-06-17 | 2018-12-05 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| CN105147713A (zh) | 2008-08-04 | 2015-12-16 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| SG174382A1 (en) | 2009-04-06 | 2011-11-28 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
| WO2010130758A1 (en) * | 2009-05-14 | 2010-11-18 | Boehringer Ingelheim International Gmbh | New combination therapy in treatment of cancer and fibrotic diseases |
| PL2451445T3 (pl) | 2009-07-06 | 2019-09-30 | Boehringer Ingelheim International Gmbh | Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| PT2608792T (pt) | 2010-08-26 | 2018-01-15 | Boehringer Ingelheim Int | Métodos de administração de um inibidor de egfr |
| WO2012065071A2 (en) * | 2010-11-12 | 2012-05-18 | The Broad Institute Of Mit And Harvard | Methods of predicting response to egfr antibody therapy |
| US9295676B2 (en) | 2011-03-17 | 2016-03-29 | The Trustees Of The University Of Pennsylvania | Mutation mimicking compounds that bind to the kinase domain of EGFR |
| WO2012125913A1 (en) | 2011-03-17 | 2012-09-20 | The Trustees Of The University Of Pennsylvania | Methods and use of bifunctional enzyme-building clamp-shaped molecules |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| CN102838590B (zh) * | 2011-06-21 | 2014-07-09 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
| EP2831589B1 (en) | 2012-03-28 | 2018-04-18 | Dana-Farber Cancer Institute, Inc. | C-raf mutants that confer resistance to raf inhibitors |
| JP2015527564A (ja) * | 2012-06-07 | 2015-09-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 自己免疫抗体 |
| WO2014004543A1 (en) * | 2012-06-25 | 2014-01-03 | Mone Zaidi Consulting, Inc. | Combination cancer therapy using bisphosphonates and anti-egfr agents |
| CA2907152A1 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| CA2918225C (en) | 2013-07-17 | 2023-11-21 | Foundation Medicine, Inc. | Methods of treating urothelial carcinomas |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| KR20180018551A (ko) | 2015-06-12 | 2018-02-21 | 프레세니어스 카비 온콜로지 리미티드 | 아파티닙 유리 염기 및 아파티닙 디말레에이트의 다형체 형태 |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
| EP3337461A1 (en) * | 2015-08-21 | 2018-06-27 | Fresenius Kabi Oncology Ltd | Pharmaceutical compositions comprising afatinib |
| EP3446704A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| CN110022878A (zh) * | 2016-11-03 | 2019-07-16 | 密执安大学评议会 | Egfr/pi3k的小分子双重抑制剂及其用途 |
| MA46852A (fr) * | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| RU2663929C2 (ru) * | 2016-12-22 | 2018-08-13 | 3СМ Биотрон Инк. | Использование производного соединения тиохромено[2,3-с]хинолин-12-она для лечения немелкоклеточного рака легких |
| US10292984B2 (en) | 2017-02-14 | 2019-05-21 | Isofol Medical Ab | Methods for increasing blood plasma 2′-deoxyuridine (dUrd) and thymidylate synthase inhibition |
| SG11202002060XA (en) * | 2017-09-08 | 2020-04-29 | Univ Colorado Regents | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers |
| KR20210144844A (ko) * | 2019-03-29 | 2021-11-30 | 아스트라제네카 아베 | 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙 |
| WO2024022080A1 (zh) * | 2022-07-29 | 2024-02-01 | 东北大学 | Plk4靶向药物在治疗对铂类药物耐药型肿瘤中的应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6442472A (en) | 1987-08-10 | 1989-02-14 | Kanebo Ltd | Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| MX9707453A (es) | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| IL120302A0 (en) | 1996-03-27 | 1997-06-10 | Pfizer | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| US6251912B1 (en) * | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| WO1999033980A2 (en) | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| DE19825591A1 (de) * | 1998-06-09 | 1999-12-23 | Jenapharm Gmbh | Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata |
| BR9914164A (pt) | 1998-09-29 | 2001-06-26 | American Cyanamid Co | Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| DE19911366A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19908567A1 (de) | 1999-02-27 | 2000-08-31 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| TR200102505T2 (tr) | 1999-02-27 | 2003-01-21 | Boehringer Ingelheim Pharma Kg | 4-amino-kinazolin ve kinolin türevleri. |
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| EE04748B1 (et) | 1999-06-21 | 2006-12-15 | Boehringer Ingelheim Pharma Kg | Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| IL141235A (en) | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
| KR100817423B1 (ko) | 2000-03-13 | 2008-03-27 | 와이어쓰 홀딩스 코포레이션 | 시아노퀴놀린을 포함하는 결장 폴립의 치료 또는 억제를 위한 약제학적 조성물 |
| US20060063752A1 (en) * | 2000-03-14 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| ES2267748T3 (es) * | 2000-04-07 | 2007-03-16 | Astrazeneca Ab | Compuestos de quinazolina. |
| US6627634B2 (en) * | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| ATE350378T1 (de) | 2000-04-08 | 2007-01-15 | Boehringer Ingelheim Pharma | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE10017539A1 (de) | 2000-04-08 | 2001-10-11 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7084136B2 (en) * | 2000-06-02 | 2006-08-01 | Shionogi & Co., Ltd. | Drug composition antagonistic to both PGD2/TXA2 receptors |
| DE10042059A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| DE10042062A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung |
| US6740651B2 (en) * | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| DE10042058A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6656946B2 (en) * | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6653305B2 (en) * | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| US6403580B1 (en) * | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| DE10042060A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10042064A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| ATE369894T1 (de) | 2000-11-22 | 2007-09-15 | Novartis Pharma Gmbh | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
| US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| CA2476008C (en) | 2002-03-30 | 2011-12-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| DE10217689A1 (de) | 2002-04-19 | 2003-11-13 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| US20040044014A1 (en) * | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| US20030225079A1 (en) * | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
| DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| PE20040945A1 (es) * | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| US7223749B2 (en) * | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| DE10307165A1 (de) | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| DE10326186A1 (de) | 2003-06-06 | 2004-12-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7456189B2 (en) * | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| DE10345875A1 (de) | 2003-09-30 | 2005-04-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| CN101501211A (zh) * | 2004-03-31 | 2009-08-05 | 综合医院公司 | 测定癌症对表皮生长因子受体靶向性治疗反应性的方法 |
| WO2006017317A2 (en) * | 2004-07-12 | 2006-02-16 | The General Hospital Corporation | Method for the treatment of disease |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| ES2364495T3 (es) | 2005-02-03 | 2011-09-05 | The General Hospital Corporation | Método para tratar cáncer resistente a gefitinib. |
| PL1948180T3 (pl) * | 2005-11-11 | 2013-09-30 | Boehringer Ingelheim Int | Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2 |
| CA2833706C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| JP5241513B2 (ja) * | 2006-01-26 | 2013-07-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミノクロトニルアミノ置換キナゾリン誘導体の合成方法 |
| AU2007299080B2 (en) | 2006-09-18 | 2013-04-18 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
| PE20100252A1 (es) * | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| JP2012515184A (ja) * | 2009-01-14 | 2012-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大腸がんの治療方法 |
| PL2451445T3 (pl) | 2009-07-06 | 2019-09-30 | Boehringer Ingelheim International Gmbh | Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną |
| JP2013512882A (ja) | 2009-12-07 | 2013-04-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２ |
-
2007
- 2007-09-14 AU AU2007299080A patent/AU2007299080B2/en active Active
- 2007-09-14 AT AT07820235T patent/ATE552835T1/de active
- 2007-09-14 MX MX2009002710A patent/MX2009002710A/es active IP Right Grant
- 2007-09-14 KR KR1020097007757A patent/KR20090074202A/ko not_active Ceased
- 2007-09-14 CA CA002663599A patent/CA2663599A1/en not_active Abandoned
- 2007-09-14 NZ NZ576065A patent/NZ576065A/en unknown
- 2007-09-14 WO PCT/EP2007/059735 patent/WO2008034776A1/en not_active Ceased
- 2007-09-14 PL PL07820235T patent/PL2068880T3/pl unknown
- 2007-09-14 SI SI200730957T patent/SI2068880T1/sl unknown
- 2007-09-14 US US12/441,180 patent/US8877764B2/en active Active
- 2007-09-14 BR BRPI0717586-8A patent/BRPI0717586A2/pt not_active IP Right Cessation
- 2007-09-14 JP JP2009528693A patent/JP2010503717A/ja active Pending
- 2007-09-14 PT PT07820235T patent/PT2068880E/pt unknown
- 2007-09-14 EP EP07820235A patent/EP2068880B1/en not_active Revoked
- 2007-09-14 DK DK07820235.5T patent/DK2068880T3/da active
- 2007-09-14 ES ES07820235T patent/ES2385613T3/es active Active
- 2007-09-14 RU RU2009114414/15A patent/RU2492864C2/ru active
-
2009
- 2009-03-16 IL IL197605A patent/IL197605A0/en unknown
-
2012
- 2012-07-06 CY CY20121100603T patent/CY1112896T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2068880T3 (da) | 2012-07-23 |
| RU2009114414A (ru) | 2010-12-27 |
| JP2010503717A (ja) | 2010-02-04 |
| BRPI0717586A2 (pt) | 2013-10-29 |
| WO2008034776A1 (en) | 2008-03-27 |
| IL197605A0 (en) | 2009-12-24 |
| PL2068880T3 (pl) | 2012-09-28 |
| ATE552835T1 (de) | 2012-04-15 |
| EP2068880B1 (en) | 2012-04-11 |
| PT2068880E (pt) | 2012-07-12 |
| US8877764B2 (en) | 2014-11-04 |
| CY1112896T1 (el) | 2016-04-13 |
| KR20090074202A (ko) | 2009-07-06 |
| US20090318480A1 (en) | 2009-12-24 |
| CA2663599A1 (en) | 2008-03-27 |
| NZ576065A (en) | 2011-12-22 |
| ES2385613T3 (es) | 2012-07-27 |
| MX2009002710A (es) | 2009-03-25 |
| RU2492864C2 (ru) | 2013-09-20 |
| AU2007299080A1 (en) | 2008-03-27 |
| AU2007299080B2 (en) | 2013-04-18 |
| EP2068880A1 (en) | 2009-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL197605A0 (en) | Method for treating cancer harboring egfr mutations | |
| AU2012257727B2 (en) | Method for EGFR directed combination treatment of cancer | |
| Bunn Jr et al. | Epidermal growth factor receptor expression, signal pathway, and inhibitors in non–small cell lung cancer | |
| Ciardiello et al. | A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor | |
| Ford et al. | Targeting epidermal growth factor receptor in head and neck cancer | |
| IL184791A (en) | Gaffitinib-Resistant Cancer Treatment Compounds A method to treat gafitinib-resistant cancer with an EGFR gene t790m using irreversible EGFR inhibitors | |
| US20100130493A1 (en) | Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer | |
| NO20062181L (no) | Metode for fremstilling av aminokrotonylforbindelser | |
| LoRusso | Phase I studies of ZD1839 in patients with common solid tumors | |
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| WO2006110175A3 (en) | Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor | |
| ATE361746T1 (de) | Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin | |
| MY137835A (en) | Quinazoline derivatives as src tyrosine kinase inhibitors | |
| TW200603804A (en) | Treatment with irinotecan (cpt-11) and an EGFR-inhibitor | |
| RU2010119922A (ru) | Усовершенствованное противоопухолевое лечение | |
| JP2007526888A (ja) | Ａｚｄ２１７１およびｚｄ１８３９を含む癌組合せ療法 | |
| TW200608959A (en) | Treatment with oxaliplatin and an egfr-inhibitor | |
| Bell et al. | Minocycline-induced hyperpigmentation in a patient treated with erlotinib for non-small cell lung adenocarcinoma | |
| Ciardiello et al. | Zd1839 (Iressa™): Preclinical Studies and Pharmacology | |
| AU2003252976B2 (en) | Combination of VEGF receptor tyrosine kinase inhibitors for treatment of cancer | |
| SAANDs et al. | Osi Pharmaceuticals Inc–‘425’on 5/30/03 re: Cell Pathways Inc/DE | |
| HK1190637B (en) | Method for egfr directed combination treatment of cancer | |
| HK1190637A (en) | Method for egfr directed combination treatment of cancer |